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Objectives: To study the fasciocidal properties of artesunate and artemether in the rat model and in vitro.
Methods: Adult Fasciola hepatica were exposed in vitro to 1, 10 and 100 mg/mL of artesunate, artemether
and dihydroartemisinin for 72 h. FemaleWistar ratswere administered a single oral dose of artesunate and
artemether (100–400 mg/kg) commencing 3 or 10–14 weeks post-infection and worm burden reductions
were assessed against infected but untreated control rats. F. hepatica were also observed by scanning
electron microscopy (SEM) after recovery from bile ducts of rats given a single oral dose of 200 mg/kg
artesunate 24 and 72 h post-treatment.
Results: F. hepatica exposed for 72 h to10 mg/mL of artesunate, artemether and dihydroartemisinin in vitro
showed poor mobility, swelling of the worm body, roughness, damage of the tegument and blebbing.
Exposure to drug concentrations of 100mg/mL resulted in the death of all F. hepatica by 72 h. One hundred
per cent worm burden reductions were achieved in rats infected with adult F. hepatica after treatment with
artesunate andartemether at 400 and200mg/kg, respectively.Administrationof artesunate andartemether
atadoseof200mg/kg toratsharbouring juvenileF.hepatica resulted inwormburdenreductionsof46%and
82%, respectively. F. hepatica recovered from rats’ bile ducts 24 h after administration of 200 mg/kg
artesunate showed normal activity and SEM observations revealed that there was no visible damage.
Seventy-two hours post-treatment F. hepatica displayed very poor mobility and there was focal swelling
of the tegument and spines.
Conclusions: Artesunate and artemether exhibit promising fasciocidal activities, with the latter showing
better tolerability by the hosts.
Keywords: Fasciola hepatica, food-borne trematodiasis, artemisinin, dihydroartemisinin, in vitro studies, in vivo
studies, scanning electron microscopy
Introduction
Fascioliasis (fasciolosis) is caused by liver flukes of the species
Fasciola hepatica and Fasciola gigantica. It is a zoonotic disease
of great veterinary importance and considerable public health
significance. In humans, an infection with Fasciola spp. occurs
through oral ingestion of metacercariae either through consump-
tion of uncooked or unwashed aquatic plants, or through drinking
contaminated water.1 Chronic infections can lead to severe dis-
abling diseases, including hepatic lesions, fibrosis and chronic
inflammation of the bile ducts.1,2 An estimated 91 million people
are at risk of becoming infected mainly in the Andean countries
of South America, Cuba, Western Europe, Egypt and the Islamic
Republic of Iran.3 It is estimated that between 2.4 and 17 million
people are infected with F. hepatica and/or F. gigantica.4,5
Treatment options for fascioliasis are still unsatisfactory and
hence there is a pressing need for new trematocidal drugs.6,7
Bithionol, emetine and dehydroemetine are commonly used
drugs for the treatment of these diseases, but all three agents
can cause serious adverse effects.8,9 Triclabendazole is currently
the most efficacious and best tolerated drug for the treatment
of fascioliasis, but the drug is so far registered in only four
countries.10
Since the discovery of the outstanding antimalarial properties
of artemisinin in the early 1970s by Chinese scientists,11,12
followed by the synthesis of several semi-synthetic derivatives
(e.g. arteether, artemether and artesunate), millions of malaria
patients have been treated with these drugs.13,14 Three studies
are worth highlighting with regard to the effect of artemisinins on
food-borne trematodiasis. First, administration of artemether and
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dihydroartemisinin-carbonate at daily doses of 30–60 mg/kg for
five consecutive days to rats infected with Clonorchis sinensis
resulted in worm burden reductions of 82–100%.12 Second,
administration of artemisinin at 500 mg twice daily for 5 days
to C. sinensis-infected patients in northern Vietnam reduced
infection intensity only marginally.15 Finally, we have recently
documented that artemisinin and its semi-synthetic derivatives
are active against Echinostoma caproni, an intestinal trematode,
both in vitro and in the mouse model. Administration of a single
oral dose of artesunate or artemether at 700 and 1100 mg/kg
respectively, cured the E. caproni-infected mice.7
In the light of the promising trematocidal activities of the
artemisinins, this study aimed at: (i) evaluating the fasciocidal
properties of artesunate and artemether and their metabolite
dihydroartemisinin in vitro; (ii) assessing the therapeutic potential
of a single oral dose of artesunate and artemether employing the
F. hepatica–rat model; and (iii) investigating drug-induced alter-
ations in vivo by means of scanning electron microscopy (SEM).
Materials and methods
Ethical clearance, drugs, parasites and rats
All animal studies presented here were approved by the local gov-
ernment based on Swiss national regulations (permission no. 2070).
Artesunate was obtained from Mepha AG (Aesch, Switzerland),
artemether was provided by Kunming Pharmaceutical Cooperation
(Kunming, P.R. China) and dihydroartemisinin was the product of
Hoffman-La Roche (Basel, Switzerland). Drugs were prepared in
homogeneous suspensions in 7% (v/v) Tween-80 and 3% (v/v) etha-
nol shortly before oral administration. F. hepatica metacercariae
were purchased from G. Graham (Addlestone, UK).
Female Wistar rats (n = 64; age: 5 weeks; weight: 100 g) were
purchased from RCC (Itingen, Switzerland). Rats were kept in
groups of five in macrolon cages in environmentally controlled con-
ditions (temperature: 25C; humidity: 70%; 12 h light and 12 h
dark cycle) and acclimatized for 1 week. They had free access to
water and rodent food (Rodent Blox from Eberle NAFAG; Gossau,
Switzerland).
In vitro studies
A total of three rats were infected with 30 metacercariae by gavage.
Twelve weeks post-infection rats were killed and all F. hepatica were
recovered from the central bile duct. The trematodes were washed in
several changes of 0.9% (w/v) NaCl solution and incubated in
six-well plates (Costar) (two per well) containing 5 mL NCTC
135 culture medium (Gibco), supplemented with antibiotics
(50 mg/mL streptomycin and 50 U/mL penicillin; Gibco). Two
trematodes were used for each control and experimental group.
Stock solutions of artesunate, artemether and dihydroartemisinin at
10 mg/mL were prepared with 60% (v/v) DMSO for immediate
use. The flukes were incubated with three serial drug dilutions of
1, 10 and 100 mg/mL for 72 h. Each drug concentration was evalu-
ated in duplicate. The control well contained the highest concentra-
tion of solvent; 0.06% (v/v) DMSO. Cultures were kept at 37C in
an atmosphere of 5% CO2 and observed after exposure for 24, 48 and
72 h under a dissecting microscope. F. hepatica were considered
dead if no movement was observed for 2 min.
In vivo studies
To study the effect of the artemisinins on adult F. hepatica, 40 rats
were each infected intragastrically with 30 metacercarial cysts of
F. hepatica. Ten to 14 weeks post-infection, six groups of five
rats were treated orally with either artesunate or artemether at a
single dose ranging from 100 to 400 mg/kg. Ten untreated rats served
as control (control 1).
For drug evaluation on juvenile F. hepatica 18 rats were each
infected with 30 F. hepatica metacercariae. Three weeks post-
infection two groups of five rats each were treated with
artesunate and artemether at a single oral dose of 200 mg/kg.
Eight untreated rats served as control (control 2).
Twelve days post-treatment, rats were euthanized by CO2. At
necropsy F. hepatica were harvested from the excised bile ducts
and counted. The effect of the drugs was assessed by comparing the
mean number of F. hepatica in any treatment group with that of the
respective control group. Differences were tested for significance
using an unpaired two-tailed Student’s t-test, allowing for unequal
variance. The data were considered significant with a P value <0.05.
Statistical analyses were done with version 9.0 of the STATA
software (StataCorp, College Station, TX, USA).
SEM observations
Three rats were each infected intragastrically with 30 metacercarial
cysts of F. hepatica. Fourteen weeks post-infection two rats were
treated intragastrically with artesunate at a single dose of 200 mg/kg.
The first rat was euthanized 24 h post-treatment and the second
one at 72 h by CO2. At necropsy F. hepatica were harvested
from the excised bile ducts. F. hepatica recovered from the untreated
rat served as control. Four flukes were examined from each rat. The
flukes were washed quickly in 0.9% (w/v) NaCl solution and imme-
diately fixed with 2.5% glutaraldehyde (v/v) in a phosphate-buffered
saline (PBS) buffer for 24 h at room temperature. After rinsing with
PBS buffer the specimen were washed with distilled water, dehy-
drated and critically point dried (Bomar SPC-900; Tacoma, USA).
After sputter coating with gold of 20 nm (Baltec Med 020, Tucson,
USA) F. hepatica were mounted on aluminium stubs and observed
in a high resolution SEM (Philips XL30 ESEM; Eindhofen, The
Netherlands) at an accelerating voltage of 5 kV.
Results
In vitro studies
Table 1 summarizes the observed mortality and morphological
alterations of adult F. hepatica after exposure to artesunate,
artemether or dihydroartemisinin at different concentrations
in vitro. Exposure to artesunate, artemether or dihydroartemisinin
at 100 mg/mL resulted in the death of all trematodes by 72 h.
Flukes displayed a coiled appearance, indistinct internal structure,
blebbing or roughness.
F. hepatica exposed for 24 h to a medium containing 10 mg/mL
of artesunate, artemether or dihydroartemisinin showed normal
movements. By 48 h they showed reduced activity and numerous
blebs could be seen along the surface of those flukes exposed to
artemether. Seventy-two hours after incubation two trematodes
each were dead in the artemether and artesunate wells, and one
trematode had died in the dihdyroartemisinin well. The remaining
flukes showed swelling, indistinction in internal tissues, but they
still exhibited some activity.
Finally, F. hepatica exposed to 1 mg/mL of artesunate,
artemether or dihydroartemisinin in vitro contracted less fre-
quently than control specimens after an observation period of
72 h, but no tegumental damage could be seen.
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Control flukes were moving normally with no evidence of
damage 72 h after incubation.
Effect of artesunate and artemether on adult F. hepatica
in vivo
The effects of artesunate and artemether on 10 to 14-week-old
adult F. hepatica harboured in rats are summarized in Table 2.
Administration of artesunate or artemether at a single oral dose
of 400 mg/kg resulted in worm burden reductions of 100%. At half
this dose, worm burden reductions of 100 and 71% were achieved
with artemether and artesunate, respectively. The lowest oral
dose investigated, i.e. 100 mg/kg was not effective, yielding
only low worm burden reductions of 30% for both compounds.
Artemether tended to be better tolerated by the rats than
artesunate; three rats died 24–96 h following an oral dose of
Table 1. Observed mortality and morphological features of adult F. hepatica after exposure in vitro to dihydroartemisinin, artemether
and artesunate at three different concentrations
Concentration
(mg/mL)
No. of flukes
observed
No. of flukes dead and morphological features after incubation for
Treatment 24 h 48 h 72 h
Dihydroartemisinin 1 4 0/4 0/4 0/4 slightly reduced mobility
10 4 0/4 0/4 reduced mobility 1/4 reduced mobility,
roughness of body surface
100 4 4/4 flukes had coiled
appearance,
extensive blebbing
in anterior part and
indistinct internal structure
4/4 4/4
Artesunate 1 4 0/4 0/4 0/4 slightly reduced mobility
10 4 0/4 0/4 reduced mobility 2/4 reduced mobility, swelling,
indistinct internal structure
100 4 0/4 strongly reduced
mobility
4/4 flukes displayed
extensive
tegumental damage
4/4
Artemether 1 4 0/4 0/4 0/4 slightly reduced mobility
10 4 0/4 0/4 reduced mobility,
numerous blebs
2/4 reduced mobility, numerous
blebs, swelling, indistinct
internal structure
100 4 0/4 reduced mobility 0/4 roughness and
blebs visible
4/4 indistinct internal
structure, swollen body
Control – 4 0/4 normal movement
and no damage visible
0/4 normal movement
and no damage visible
0/4 normal movement
and no damage visible
Tables 2. Effect of artesunate and artemether against adult F. hepatica harboured in rats
Dose
(mg/kg)
No. of rats
investigated
No. of rats
that died
No. of rats
curedc
Mean worm
burden (SD)
No. of flukes
recovered
Total worm
burden reduction (%) P valueTreatment live dead
Control 1 – 10 0 0 8.4 (4.2) 84 0 – –
Control 2 – 8 0 0 5.6 (2.7) 45 0 –
Artesunate 100a 5 0 2 5.8 (7.7) 28 1 30 0.799
200a 5 1 1 2.5 (3.1) 10 6 71 0.021
400a 5 3 2 0 0 0 100 <0.001
Artemether 100a 5 0 1 5.8 (4.0) 29 0 30 0.561
200b 5 0 5 0 0 6 100 <0.001
400b 5 0 5 0 0 2 100 <0.001
aWorm burden reduction assessed by comparing the mean number of F. hepatica with that of control 1.
bWorm burden reduction assessed by comparing the mean number of F. hepatica with that of control 2.
cSignifies the number of rats without flukes.
Fasciolicidal activity of artesunate and artemether
1141
400 mg/kg artesunate, while none of the rats died after
administration of artemether at the same dose.
Effect of artesunate and artemether on juvenile F. hepatica
in vivo
In Table 3, we present the effect of artesunate and arte-
mether on juvenile (3-week-old) F. hepatica harboured in rats.
A single oral dose of 200 mg/kg of artesunate and
artemether yielded worm burden reductions of 46% and 82%,
respectively.
SEM observations
The morphological features of adult F. hepatica collected
from untreated control rats were in agreement with previous
reports.16,17 Figure 1 shows the oral sucker (a) and the mid-
ventral tegument (b) of F. hepatica recovered from these
control rats.
We examined four F. hepatica recovered from rats 24 h after
administration of a single dose of 200 mg/kg artesunate. They
showed normal movement. There was no apparent alteration in
the tegument of these flukes, with the exception of one specimen
showing focal swelling of the tegument and some sunken spines
near the tail (Figure 2a). Seventy-two hours post-treatment 4
F. hepatica were recovered from the bile duct, which showed
only feeble activity or were without motility and appeared pale
with no evidence of gut contents. Minor damage was visible as
the tegument covering the spines appeared to be split open, and
sunken spines were observed near the oral sucker rim or in the
lateral surface of the oral sucker (Figure 2b and c). We also
observed focal swelling and furrowing of the ventral tegument
with some roughness and damaged spines (Figure 2d and e). No
apparent damage of the dorsal tegument was observed.
Discussion
To our knowledge, this is the first time that derivatives of
artemisinin have been tested for their effect against F. hepatica.
We have assessed the dose–response relationships following
administration of single oral doses in the F. hepatica–rat
model. We found that both artesunate and artemether were highly
efficacious against adult F. hepatica; complete worm burden
reductions were obtained with artesunate and artemether admin-
istered at 400 and 200 mg/kg, respectively. In addition, admin-
istration of artemether at a dose of 200 mg/kg to rats infected
with juvenile F. hepatica resulted in a worm burden reduction
of 82%. Our results are important as there is an urgent need to
develop new therapeutic agents against food-borne trematodiasis
in general, and fascioliasis in particular. Triclabendazole is
the only drug currently available for treatment of patients
with fascioliasis.10 However, triclabendazole is presently
registered in only four countries and there is considerable
concern that resistance might be developing; a phenomenon,
which is already widespread in cattle and sheep in several
countries.10,18
Table 3. Effect of artesunate and artemether against juvenile F. hepatica harboured in rats
Treatment
Dose
(mg/kg)
No. of rats
investigated
No. of rats
that died
No. of
rats cureda
Mean worm
burden (SD)
Total worm
burden reduction (%) P value
Control 2 – 8 0 – 5.6 (2.7) –
Artesunate 200 5 0 1 3.0 (2.7) 46 0.125
Artemether 200 5 0 1 1.0 (0.7) 82 <0.001
aSignifies the number of rats without flukes.
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Figure 1. SEM observation of an oral sucker (OS) (a) and tegument with spines
(TS) in the mid-ventral region (b) of adult F. hepatica recovered from a
non-treated control rat.
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In vitro exposure of F. hepatica to a high concentration of
100 mg/mL of dihydroartemisinin, the main metabolite of the
artemisinins, resulted in a more rapid killing of the trematodes
when compared with artesunate and artemether. These
observations are in agreement with previous findings that di-
hydroartemisinin was the most rapidly acting artemisinin
derivative on E. caproni in vitro.7 Hence, dihydroartemisinin
might play an important role in the curing of F. hepatica infec-
tions in the rat. However, although the conversion of artesunate to
dihydroartemisinin is 6-fold greater when compared with arte-
mether,19 artemether was slightly more active in vivo. Hence,
most likely not only the primary metabolite but also the mother
00053965 Z M BUni Basel50 µm
(a)
STS
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Figure 2. SEM observation of adult F. hepatica following the administration of artesunate at a dose of 200 mg/kg. There is focal swelling (s) of the lateral ventral
surface in the tail 24h post-treatment (a), split tegumental spines (STS)near the rimof the oral sucker 72hpost-treatment (b), swellingwith sunken spines (SS) near the
rim of the oral sucker 72 h post-treatment (c), and swelling (s) and furrowing (f) of the tegument and spines in the mid-ventral region 72 h post-treatment (d and e).
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compounds contribute to the observed in vivo activity. This claim
is supported by the observation that all three derivatives showed
an equal dose–response relationship in vitro. We did not include
dihydroartemisinin in our in vivo investigations, as oral artesunate
was found to have pharmacokinetic advantages over oral
dihydroartemisinin.20
Our experiments revealed that artemether tended to be
better tolerated than artesunate. While no adverse events could
be observed following administration of a single oral dose of
600 mg/kg artemether (unpublished observation), three of five
rats died 24–96 h after administration of a single oral dose of
400 mg/kg artesunate. F. hepatica infections have been described
to dramatically impair the integrity and functionality of the
microsomal drug metabolizing mono-oxygenase system,21
which is involved in the elimination of the artemisinins.22–24
Dihydroartemisinin, for example, is a potent inhibitor of
CYP1A2,22 one of the cytochrome enzymes which might be
altered during chronic fascioliasis. As mentioned, dihy-
droartemisinin plasma levels are much higher following the
administration of artesunate when compared with artemether,
as artesunate is rapidly hydrolysed into dihydroartemisinin in
the stomach.19,25 It follows that toxic levels of this metabolite
might accumulate in F. hepatica-infected rats after administra-
tion of a high dose of artesunate. Hence, the safety margin of
artesunate might decrease during fascioliasis.
Considerably lower doses of artesunate and artemether
achieved significant worm burden reductions in the
F. hepatica–rat model, when compared with our previous results
obtained in the E. caproni–mouse model. For example, while a
dose of 200 mg/kg artemether achieved a worm burden reduction
of 100% in F. hepatica-infected rats, no effect was seen with a
3-fold higher dose administered to E. caproni-infected mice. This
result might be explained by differences in the pharmacokinetics
and metabolism between the two rodent models as well as higher
drug levels of the two artemisinin derivatives and its main
metabolite dihydroartemisinin in the liver and bile duct, when
compared with the small intestine. Knowledge on the absorption
phase of the artemisinins is incomplete. While a low bioavail-
ability of the parent drugs (19–35%) was observed when testing
different formulations of all derivatives in rats,19 the absolute
bioavailability of artesunate was found to be 61% in malaria
patients.26
Our in vitro and in vivo studies have shown that artesunate
and artemether act rather slowly on F. hepatica. Twelve days
post-treatment dead flukes could be recovered from the rat’s bile
ducts. Our SEM observations revealed that 24 h post-treatment
with artesunate, trematodes collected from the bile duct showed
activity and no external damage could be detected. Seventy-two
hours post-treatment, flukes were still recovered from the bile
duct but showed feeble activity. Tegumental damage was quite
limited and hence both the tegument and suckers do not seem to
be the main targets for artesunate to exert its fasciocidal effect. In
contrast, after treatment of rats with clorsulon, a sulphonamide
fasciolicide, flukes were dead by 25–30 h and expelled by
50–60 h.27 Flukes that could be recovered 72 h post-treatment
with clorsulon were severely damaged and showed, for example,
a widespread disruption with sloughing of the apical membrane.16
Numerous studies carried out in different animal models
and human clinical trials established an evidence base that arte-
mether and artesunate are efficacious drugs against the juvenile
stages of the biologically related blood digeneans in the genus
Schistosoma.28,29 Artemether seems to be more effective than
artesunate against different developmental stages of both trema-
todes, F. hepatica in the rat and Schistosoma mansoni harboured
in mice (reviewed in ref. 30). However, two marked differences
between schistosomes and F. hepatica following administration
of artemisinins to suitable animal models are worth highlighting.
First, while we have demonstrated that both juvenile and adult
F. hepatica are affected by the artemisinins, adult schistosomes
are less susceptible to these drugs. For example, administration of
six daily doses of 200 mg/kg artemether resulted in a worm
burden reduction of only 39% in the adult S. mansoni–mouse
model.31 Finally, in contrast to our SEM findings, severe changes
to the tegument of S. mekongi, characterized by vacuolization,
collapse and peeling, were observed by means of SEM 1–3 days
after administration of artesunate.32 Hence, one might speculate
that artesunate and artemether exert different mechanism of
actions on these two genera of flukes.
In conclusion, our study shows the fasciocidal properties of
artesunate and artemether. This finding raises hope for novel
approaches towards trematocidal drugs.
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